We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
LGC Clinical Diagnostics

Download Mobile App




Mosquitoes Genetically Modified as Malaria-Blocking Insect Model

By LabMedica International staff writers
Posted on 02 Dec 2015
Scientists used CRISPR gene editing to create a parasite-resistant strain of Anopheles mosquito capable of rapidly introgressing malaria-blocking genes into a mosquito population through its progeny, ultimately eliminating the insects’ ability to transmit the Plasmodium falciparum parasite to humans. More...
This new model represents a notable advance in the effort to establish an anti-malarial mosquito population, which with further development could help eradicate a disease that sickens millions worldwide each year.

To create this breed, researchers at the University of California at Irvine and San Diego (CA, USA) inserted a DNA element into the germ-line of Anopheles stephensi (a leading malaria vector in Asia) that resulted in the gene, for preventing parasite transmission, being passed on to an astonishing 99.5% of offspring, resulting in near-Mendelian inheritance ratios of the transgene.

“This opens up the real promise that this technique can be adapted for eliminating malaria,” said Anthony James, professor at UCI. For nearly 20 years, the James lab has focused on engineering anti-disease mosquitoes. His anti-dengue fever models have been tested in cage trials in Mexico and in 2012 he helped show that antibodies adapted from immune system of mice can be introduced into mosquitoes to impair pathogen biology. This trait, though, was inherited by only about half of the progeny.

UCSD biologists Ethan Bier and Valentino Gantz working with Drosophila recently announced the development of a new CRISPR-based mutagenic chain-reaction method for generating mutations in both copies of a gene, allowing for germ-line transmission of mutations with 95% inheritance rate. The two groups collaborated to apply Bier and Gantz’s method to James’ mosquitoes. Prof. Gantz packaged antimalaria genes using the DNA-cutting Cas9 enzyme and a guide-RNA to create a genetic cassette that, when injected into a mosquito embryo, targeted a highly specific spot in the germ line DNA to insert the antimalaria antibody genes. To ensure that the element carrying the malaria-blocking antibodies had reached the desired DNA site, the researchers included in the cassette a protein that gave the progeny red fluorescence in the eyes. Amazingly, almost all offspring—99.5%—exhibited this trait.

Further testing will be needed to confirm the efficacy of the antibodies and could eventually lead to field studies. “This is a significant first step,” said James, “We know the gene works. The mosquitoes we created are not the final brand, but we know this technology allows us to efficiently create large populations.” Prof. Bier added, “The ability of this system to carry large genetic payloads should have broad applications to the future use of related Crispr-based ‘active genetic’ systems.”

The study, by Gantz VM et al., was published online ahead of print November 23, 2015, in the journal Proceedings of the National Academy of Sciences of the United States of America (PNAS).

Related Links:

University of California, Irvine 
University of California, San Diego 



Platinum Member
Xylazine Immunoassay Test
Xylazine ELISA
Verification Panels for Assay Development & QC
Seroconversion Panels
Anti-Cyclic Citrullinated Peptide Test
GPP-100 Anti-CCP Kit
Gold Member
ESR Analyzer
miniiSED™
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: QIP-MS could predict and detect myeloma relapse earlier compared to currently used techniques (Photo courtesy of Adobe Stock)

Mass Spectrometry-Based Monitoring Technique to Predict and Identify Early Myeloma Relapse

Myeloma, a type of cancer that affects the bone marrow, is currently incurable, though many patients can live for over 10 years after diagnosis. However, around 1 in 5 individuals with myeloma have a high-risk... Read more

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Technology

view channel
Image: Ziyang Wang and Shengxi Huang have developed a tool that enables precise insights into viral proteins and brain disease markers (Photo courtesy of Jeff Fitlow/Rice University)

Light Signature Algorithm to Enable Faster and More Precise Medical Diagnoses

Every material or molecule interacts with light in a unique way, creating a distinct pattern, much like a fingerprint. Optical spectroscopy, which involves shining a laser on a material and observing how... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.